Simplex Trading’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,500
| Closed | -$252K | – | 9983 |
|
|
2025
Q4 | $252K | Sell |
3,500
-38,000
| -92% | -$2.45M | ﹤0.01% | 3990 |
|
|
2025
Q3 | $1.81M | Buy |
41,500
+32,900
| +383% | +$1.33M | ﹤0.01% | 2432 |
|
|
2025
Q2 | $244K | Sell |
8,600
-1,800
| -17% | -$53.7K | ﹤0.01% | 4294 |
|
|
2025
Q1 | $307K | Sell |
10,400
-118,000
| -92% | -$3.68M | ﹤0.01% | 3897 |
|
|
2024
Q4 | $3.73M | Buy |
128,400
+126,500
| +6,658% | +$5.29M | ﹤0.01% | 1692 |
|
|
2024
Q3 | $87K | Sell |
1,900
-1,700
| -47% | -$73.8K | ﹤0.01% | 5378 |
|
|
2024
Q2 | $147K | Sell |
3,600
-600
| -14% | -$17.2K | ﹤0.01% | 4956 |
|
|
2024
Q1 | $107K | Sell |
4,200
-12,700
| -75% | -$199K | ﹤0.01% | 5506 |
|
|
2023
Q4 | $152K | Sell |
16,900
-3,700
| -18% | -$24.7K | ﹤0.01% | 4959 |
|
|
2023
Q3 | $131K | Buy |
20,600
+5,100
| +33% | +$43.9K | ﹤0.01% | 4815 |
|
|
2023
Q2 | $171K | Sell |
15,500
-600
| -4% | -$7.53K | ﹤0.01% | 4480 |
|
|
2023
Q1 | $247K | Buy |
16,100
+4,700
| +41% | +$103K | ﹤0.01% | 4086 |
|
|
2022
Q4 | $252K | Buy |
11,400
+9,600
| +533% | +$143K | ﹤0.01% | 3937 |
|
|
2022
Q3 | $29K | Sell |
1,800
-6,600
| -79% | -$126K | ﹤0.01% | 7118 |
|
|
2022
Q2 | $122K | Buy |
8,400
+300
| +4% | +$4.46K | ﹤0.01% | 5287 |
|
|
2022
Q1 | $149K | Buy |
8,100
+8,000
| +8,000% | +$136K | ﹤0.01% | 5594 |
|
|
2021
Q4 | $2K | Buy |
+100
| New | +$2.39K | ﹤0.01% | 10042 |
|
Other funds holding RNAM
Simplex Trading's RNAM Position: Q1 2026 in Review
Simplex Trading sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 38,607 shares — an estimated $2.78M sold.
Simplex Trading first reported a position in RNAM in Q4 2021 and held it in 10 quarters. The position peaked at $2.78M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Simplex Trading reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Simplex Trading sold 38,607 Avidity Biosciences shares in Q1 2026, an estimated $2.78M.
- Simplex Trading first reported a position in Avidity Biosciences in Q4 2021 and held it in 10 quarters.
- Simplex Trading's Avidity Biosciences position peaked at $2.78M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.